The ROAR (Rare Oncology Agnostic Research) trial is a multicenter, open-label, and phase II basket trial designed to evaluate the efficacy and safety of dabrafenib (oral BRAF inhibitor) plus trametinib (oral MEK inhibitor) for patients with rare cancers harboring BRAF V600E mutations. Here, BRAF is linked to cancer.